QURE – uniQure N.V.
uniQure N.V.QURE
$12.81Name : uniQure N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $701,328,320.00
EPSttm : -4.92
uniQure N.V.
$12.81
2.59%$0.34Float Short %
11.07
Margin Of Safety %
Put/Call OI Ratio
0.36
EPS Next Q Diff
EPS Last/This Y
1.33
EPS This/Next Y
0.64
Price
12.81
Target Price
35.5
Analyst Recom
1.29
Performance Q
-2.66
Relative Volume
0.93
Beta
0.05
Ticker: QURE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | QURE | 9.29 | 0.15 | 0.53 | 38702 |
| 2025-04-15 | QURE | 9.64 | 0.15 | 0.14 | 38817 |
| 2025-04-16 | QURE | 9.41 | 0.14 | 0.33 | 48395 |
| 2025-04-17 | QURE | 12.99 | 0.13 | 1.00 | 48673 |
| 2025-04-18 | QURE | 13 | 0.13 | 1.00 | 48673 |
| 2025-04-21 | QURE | 13.31 | 0.33 | 0.30 | 45102 |
| 2025-04-22 | QURE | 14.38 | 0.33 | 0.93 | 47389 |
| 2025-04-23 | QURE | 14.31 | 0.33 | 0.17 | 47770 |
| 2025-04-24 | QURE | 14.25 | 0.33 | 0.81 | 49143 |
| 2025-04-25 | QURE | 14.18 | 0.3323227987337 | 2.4343065693431 | 49661 |
| 2025-04-28 | QURE | 13.97 | 0.34073539629095 | 0.96373056994819 | 50173 |
| 2025-04-29 | QURE | 13.85 | 0.35 | 4.25 | 50761 |
| 2025-04-30 | QURE | 14.75 | 0.36 | 0.80 | 51951 |
| 2025-05-01 | QURE | 15 | 0.37 | 0.55 | 52641 |
| 2025-05-02 | QURE | 14.77 | 0.37 | 0.63 | 53121 |
| 2025-05-05 | QURE | 15.88 | 0.37 | 0.10 | 53300 |
| 2025-05-06 | QURE | 11.46 | 0.37 | 1.41 | 53289 |
| 2025-05-07 | QURE | 10.05 | 0.45 | 0.12 | 58609 |
| 2025-05-08 | QURE | 12.23 | 0.41 | 0.10 | 63735 |
| 2025-05-09 | QURE | 12.78 | 0.39 | 0.07 | 67957 |
| 2025-05-12 | QURE | 13.15 | 0.36 | 0.34 | 72776 |
| 2025-05-13 | QURE | 12.82 | 0.36 | 0.06 | 74815 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | QURE | 9.17 | 23.9 | 45.9 | -3.71 |
| 2025-04-15 | QURE | 9.65 | 23.9 | 38.4 | -3.71 |
| 2025-04-16 | QURE | 9.42 | 23.9 | 61.0 | -3.71 |
| 2025-04-17 | QURE | 13.00 | 23.9 | -58.4 | -3.71 |
| 2025-04-18 | QURE | 13.00 | 23.9 | 54.2 | -3.66 |
| 2025-04-21 | QURE | 13.28 | 24.6 | 49.7 | -3.66 |
| 2025-04-22 | QURE | 14.39 | 24.6 | 37.1 | -3.66 |
| 2025-04-23 | QURE | 14.39 | 25.0 | 54.2 | -3.66 |
| 2025-04-24 | QURE | 14.24 | 25.0 | 56.0 | -3.66 |
| 2025-04-25 | QURE | 14.18 | 25.0 | 55.1 | -3.64 |
| 2025-04-28 | QURE | 13.97 | 25.0 | 57.1 | -3.64 |
| 2025-04-29 | QURE | 13.86 | 25.0 | 55.6 | -3.64 |
| 2025-04-30 | QURE | 14.76 | 25.0 | 43.8 | -3.64 |
| 2025-05-01 | QURE | 15.00 | 25.0 | 50.8 | -3.64 |
| 2025-05-02 | QURE | 14.77 | 25.7 | 57.1 | -3.61 |
| 2025-05-05 | QURE | 15.89 | 25.7 | 39.6 | -3.61 |
| 2025-05-06 | QURE | 11.47 | 25.7 | 104.9 | -3.61 |
| 2025-05-07 | QURE | 10.06 | 25.7 | 82.4 | -3.61 |
| 2025-05-08 | QURE | 12.24 | 26.0 | -3.1 | -3.61 |
| 2025-05-09 | QURE | 12.78 | 26.0 | 44.6 | -3.59 |
| 2025-05-12 | QURE | 13.15 | 26.0 | 48.0 | -3.59 |
| 2025-05-13 | QURE | 12.81 | 26.0 | 59.5 | -3.59 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | QURE | -4.25 | 7.92 | 8.88 |
| 2025-04-15 | QURE | -4.25 | 7.92 | 8.88 |
| 2025-04-16 | QURE | -4.25 | 7.92 | 8.88 |
| 2025-04-17 | QURE | -4.25 | 7.92 | 8.88 |
| 2025-04-18 | QURE | -4.25 | 7.92 | 8.88 |
| 2025-04-21 | QURE | -4.25 | 9.32 | 8.88 |
| 2025-04-22 | QURE | -4.25 | 9.32 | 8.88 |
| 2025-04-23 | QURE | -4.25 | 9.32 | 8.88 |
| 2025-04-24 | QURE | -4.25 | 9.32 | 8.88 |
| 2025-04-25 | QURE | -4.25 | 9.32 | 8.88 |
| 2025-04-28 | QURE | -4.25 | 9.26 | 10.63 |
| 2025-04-29 | QURE | -4.25 | 9.26 | 10.63 |
| 2025-04-30 | QURE | -4.20 | 9.26 | 10.50 |
| 2025-05-01 | QURE | -4.20 | 9.26 | 10.50 |
| 2025-05-02 | QURE | -4.20 | 9.26 | 10.50 |
| 2025-05-05 | QURE | -4.20 | 9.79 | 10.50 |
| 2025-05-06 | QURE | -4.20 | 9.79 | 10.50 |
| 2025-05-07 | QURE | -4.20 | 9.79 | 10.50 |
| 2025-05-08 | QURE | -4.20 | 9.79 | 10.50 |
| 2025-05-09 | QURE | -4.20 | 9.79 | 10.50 |
| 2025-05-12 | QURE | -4.20 | 10.73 | 11.07 |
| 2025-05-13 | QURE | -4.20 | 10.73 | 11.07 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.97
Avg. EPS Est. Next Quarter
-0.95
Insider Transactions
-4.2
Institutional Transactions
10.73
Beta
0.05
Average Sales Estimate Current Quarter
5
Average Sales Estimate Next Quarter
6
Fair Value
Quality Score
19
Growth Score
46
Sentiment Score
19
Actual DrawDown %
82.1
Max Drawdown 5-Year %
-94.4
Target Price
35.5
P/E
Forward P/E
PEG
P/S
34.72
P/B
20.8
P/Free Cash Flow
EPS
-4.39
Average EPS Est. Cur. Y
-3.59
EPS Next Y. (Est.)
-2.95
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1077.05
Relative Volume
0.93
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
0.12
EBIT Estimation
59.5
uniQure N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 209
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
stock quote shares QURE – uniQure N.V. Stock Price stock today
news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch QURE – uniQure N.V. yahoo finance google finance
stock history QURE – uniQure N.V. invest stock market
stock prices QURE premarket after hours
ticker QURE fair value insiders trading